-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LHN7MPZEsELoatY04vvY/7x3gcUP80Zf6b31kDnULUCFqsXUajm/7L2/Tf0/jboz 1Klt3QVloUlUGBmnM7yUdg== 0000932799-03-000175.txt : 20031003 0000932799-03-000175.hdr.sgml : 20031003 20031003165107 ACCESSION NUMBER: 0000932799-03-000175 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 4 FILED AS OF DATE: 20031003 GROUP MEMBERS: ROSEMARY FANELLI SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: REGEN BIOLOGICS INC CENTRAL INDEX KEY: 0000883697 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 232476415 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-49089 FILM NUMBER: 03928338 BUSINESS ADDRESS: STREET 1: 1650 TYSONS BLVD CITY: MCLEAN STATE: VA ZIP: 22102 BUSINESS PHONE: 7038471400 MAIL ADDRESS: STREET 1: 1650 TYSONS BLVD CITY: MCLEAN STATE: VA ZIP: 22102 FORMER COMPANY: FORMER CONFORMED NAME: AROS CORP DATE OF NAME CHANGE: 20010712 FORMER COMPANY: FORMER CONFORMED NAME: APACHE MEDICAL SYSTEMS INC DATE OF NAME CHANGE: 19960426 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ALLEN & CO INC/ALLEN HOLDING INC CENTRAL INDEX KEY: 0000904807 IRS NUMBER: 931202428 STATE OF INCORPORATION: NY FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 711 FIFTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 2128328300 MAIL ADDRESS: STREET 1: 711 FIFTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10022 SC 13D/A 1 regen13d03.txt AMENDMENT OT SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* REGEN BIOLOGICS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 75884M 104 (CUSIP Number) Rosemary Fanelli Allen & Company Incorporated 711 Fifth Avenue New York, NY 10022 (212) 832-8000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) September 16, 2003 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of (paragraphs)240.13d-1 (e), 240.13d-1 (f) or 240.13d-1 (g), check the following box. [ ] Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See (paragraph)240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 75884M 104 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Allen & Company Incorporated - ------------ ------------------------------------------------------------------- - ------------ ------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (See Instructions): (a) [ ] (b) [ x ] - ------------ ------------------------------------------------------------------- - ------------ ------------------------------------------------------------------- 3. SEC Use Only - ------------ ------------------------------------------------------------------- - ------------ ------------------------------------------------------------------- 4. Source of Funds (See Instructions): WC - ------------ ------------------------------------------------------------------- - ------------ ------------------------------------------------------------------- 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e): N/A - ------------ ------------------------------------------------------------------- - ------------ ------------------------------------------------------------------- 6. Citizenship or Place of Organization: New York - ------------------- ------------------------------------------------------------ Number of Shares Beneficially Owned by Each Reporting Person 7. Sole Voting Power: 2,901,220* With ------------------------------------------------------------ ------------------------------------------------------------ 8. Shared Voting Power: 0 ------------------------------------------------------------ ------------------------------------------------------------ 9. Sole Dispositive Power: 2,901,220* ------------------------------------------------------------ ------------------------------------------------------------ 10. Shared Dispositive Power: 0 - ------------ ------------------------------------------------------------------- 11. Aggregate Amount Beneficially Owned by Each Reporting Person: 2,901,220* - ------------ ------------------------------------------------------------------- - ------------ ------------------------------------------------------------------- 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions): [X] - ------------ ------------------------------------------------------------------- - ------------ ------------------------------------------------------------------- 13. Percent of Class Represented by Amount in Row (11): 9.5%* - ------------ ------------------------------------------------------------------- - ------------ ------------------------------------------------------------------- 14. Type of Reporting Person (See Instructions): CO - ------------ ------------------------------------------------------------------- CUSIP No. 75884M 104 - -------------------------------------------------------------------------------- - ------------ ------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Allen Holding Inc. - ------------ ------------------------------------------------------------------- - ------------ ------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (See Instructions): (a) [ ] (b) [ x ] - ------------ ------------------------------------------------------------------- - ------------ ------------------------------------------------------------------- 3. SEC Use Only - ------------ ------------------------------------------------------------------- - ------------ ------------------------------------------------------------------- 4. Source of Funds (See Instructions): Not Applicable - ------------ ------------------------------------------------------------------- - ------------ ------------------------------------------------------------------- 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e): N/A - ------------ ------------------------------------------------------------------- - ------------ ------------------------------------------------------------------- 6. Citizenship or Place of Organization: Delaware - ------------------- ------------------------------------------------------------ Number of Shares Beneficially Owned by Each Reporting Person 7. Sole Voting Power: 0 With ------------------------------------------------------------ ------------------------------------------------------------ 8. Shared Voting Power: 0 ------------------------------------------------------------ ------------------------------------------------------------ 9. Sole Dispositive Power: 0 ------------------------------------------------------------ ------------------------------------------------------------ 10. Shared Dispositive Power: 0 - ------------ ------------------------------------------------------------------- 11. Aggregate Amount Beneficially Owned by Each Reporting Person: 2,901,2201* - ------------ ------------------------------------------------------------------- - ------------ ------------------------------------------------------------------- 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions): [X] - ------------ ------------------------------------------------------------------- - ------------ ------------------------------------------------------------------- 13. Percent of Class Represented by Amount in Row (11): 9.5%* - ------------ ------------------------------------------------------------------- - ------------ ------------------------------------------------------------------- 14. Type of Reporting Person (See Instructions): HC - ------------ ------------------------------------------------------------------- Item 1. Security and Issuer This Amendment No. 1 to the statement on Schedule 13D relates to the common stock, par value $0.01 per share, of Regen Biologics, Inc., a Delaware corporation (the "Issuer"). The address of the principal executive office of the Issuer is 1290 Bay Dale Drive, PMB 351, Arnold, MD 21012. Item 3. Source and Amount of Funds or Other Consideration Allen & Company Incorporated ("Allen") used working capital to purchase the Acquired Securities (as defined in Item 5(c) hereof) and paid the Issuer an aggregate purchase price of $250,000 for the Acquired Securities: Item 4. Purpose of Transaction Allen purchased the Acquired Securities for investment purposes. Allen currently has no plans or proposals which would result in any actions described in clause (a) through (j) of Item 4 of the General Instructions to the Schedule 13D. In addition, in connection with the a merger between the Aros Corporation and the Issuer on June 21, 2002, Allen, Dr. Richard Steadman, M.D., Sanderling Venture Partners IV Co-Investment Fund, L.P., Sanderling IV Biomedical Co-Investment Fund, L.P., Sanderling IV Venture Management, Sanderling Venture Partners V Co-Investment Fund, L.P., Sanderling V Biomedical Co-Investment Fund, L.P., Sanderling V Limited Partnership, Sanderling V Beteiligungs GmbH & Co. KG, Sanderling V Ventures Management, and Centerpulse USA Holding Co. (formerly Sulzer Medica Holding Co.), all former stockholders of ReGen, entered into a Stockholders' Agreement (the "Stockholders' Agreement"), dated as of June 21, 2002, whereby the parties to the Stockholders' Agreement agreed to vote all of their shares of capital stock of the Issuer in favor of certain corporate actions, including but not limited to maintaining the Issuer's board of directors at seven (7) members, electing certain individuals to the Issuer's board, amending the Issuer's certificate of incorporation to increase the number of authorized shares of common stock of the Issuer and amending the Issuer's by-laws. As previously disclosed by Allen on a Form 4 relating to the Issuer filed with the Securities Exchange Commission on December 23, 2002, the parties to the Stockholders' Agreement on December 4, 2002, executed an amendment to the Stockholders' Agreement (the "Release") pursuant to which the parties to the Stockholders' Agreement released Allen from its obligations under the Stockholders' Agreement, and as a consequence, Allen is no longer a party to the Stockholders' Agreement. Under the terms of the Release which became effective on November 26, 2002, Allen, as of the effective date, no longer shared voting power or dispositive power of any of the Issuer's securities with any of the parties to the Stockholders' Agreement. References to and descriptions of the Stockholders' Agreement and Release as set forth in this Item 4 are qualified in their entirety by reference to the copies of such agreements included as Exhibits 3 and 4, respectively, to this Amendment No. 1 to Schedule 13D, and are incorporated in their entirety in this Item 4. Item 5. Interest in Securities of the Issuer (a)......As of October 2, 2003, Allen, for purposes of Rule 13d-3 of the Securities Exchange Act of 1934, as amended, beneficially owns in the aggregate 2,901,220* shares of the Issuer's common stock (the "Shares"), which represents approximately 9.5% of the issued and outstanding shares of the Issuer's common stock (based on the number of shares reported to be outstanding by the Issuer in its Form 10-Q dated August 14, 2003). (b)......Allen has the sole power to vote or to direct the vote and to dispose or to direct the disposition of the Shares. (c)......Pursuant to the Series C Convertible Preferred Stock Purchase Agreement by and among the Issuer and certain investors, including Allen, Allen acquired for an aggregate purchase price of $250,000 (i) 557,911 shares of the Issuer's Series C Convertible Preferred Stock and (ii) warrants to purchase 52,163 shares the Issuer's common stock (collectively, the "Acquired Securities"). (d) - (e) Not applicable. Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer The transactions effected by Allen pursuant to the Purchase Agreement and the Release are describe in Item 3 hereof. The Purchase Agreement and Release are being filed as Exhibit 5 and 4, respectively. Except for the agreements described in this Item 6, to the best of Allen's knowledge, there are no other contracts, arrangements, understandings or relationships (legal or otherwise) between Allen and any persons with respect to any securities of the Issuer. Item 7. Material to Be Filed as Exhibits. Exhibit.. Description 1 Officers and Directors of Allen & Company Incorporated 2 Agreement and Plan of Merger, dated as of June 21, 2002, by and among Aros Corporation, Aros Acquisition Corp. and ReGen Biologics, Inc.++ 3 Stockholders' Agreement, dated as of June 21, 2002, by and among the several stockholders named therein.+ 4 Amendment to Stockholders' Agreement, dated as of December 4, 2002 by and among Allen and the several stockholders named therein. 5 Series C Convertible Preferred Stock Purchase Agreement by and among Regen Biologic, Inc. and certain investors, including Allen & Company Incorporated Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: October 2, 2003 Allen & Company Incorporated By: /s/ Rosemary Fanelli -------------------- Name: Rosemary Fanelli Title: Vice President, Chief Administrative Officer and Secretary Allen Holding Inc. By: /s/ Rosemary Fanelli -------------------- Name: Rosemary Fanelli Title: Vice President, Chief Administrative Officer and Secretary Footnotes: - -------- *Includes 492,785 shares issuable upon the conversion of Series A Preferred Stock, 557,911 shares issuable upon the conversion of Series C Preferred Stock and 335,289 shares issuable upon the exercise of warrants. Excludes 52,162 warrants because these warrants are not currently exercisable within 60 days. Allen Holding Inc. owns 100% of the outstanding stock of Allen & Company Incorporated and so may be deemed to beneficially own the shares which Allen & Company Incorporated owns. + Incorporated herein by reference to the Schedule 13D filed by Allen on October 21, 2002. ++ Incorporated herein by reference to Exhibit 10.1 of the 8-K filed by the Issuer on June 26, 2002 EX-99 3 regex1a.txt EXHIBIT 99.1 Exhibit 1 Officers and Directors of Allen & Company Incorporated Officers Title Herbert A. Allen President and Chief Executive Officer Herbert A. Allen III Executive Vice President Kim M. Wieland Vice President and Chief Financial Officer Rosemary Fanelli Vice President, Chief Administrative Officer and Secretary Howard M. Felson Vice President, Controller and Assistant Secretary Christine Olenchalk Vice President and Assistant Secretary Eugene Protash Vice President and Assistant Secretary Directors Herbert A. Allen III Herbert A. Allen Donald R. Keough - Chairman Kim M. Wieland EX-10 4 regex1.txt STOCKHOLDER PURCHASE AGREEMENTS Exhibit 4 AMENDMENT TO STOCKHOLDERS' AGREEMENT THIS AMENDMENT (this "Amendment") is entered into this _____ day of December, 2002 by and between ReGen Biologics, Inc., a Delaware corporation (the "Company") and the undersigned stockholders of the Company. Recitals WHEREAS, the Company (formerly known as Aros Corporation) and certain stockholders of the Company are parties to that certain Stockholders' Agreement dated as of June 21, 2002 (the "Agreement"). Capitalized terms used herein without definition shall have the meanings ascribed to such terms in the Agreement; and WHEREAS, the parties hereto desire to amend the Agreement to remove Allen & Company Incorporated ("Allen & Co.") as a party thereto and release such stockholder from all of its obligations under the Agreement, effective as of November 26, 2002. NOW, THEREFORE, in consideration of the foregoing, of the mutual promises herein contained, and of other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending legally to be bound, hereby agree as follows: 1. The Agreement is hereby amended by removing Allen & co. as a party to the Agreement and releasing such stockholder from all of its obligations under the Agreement, including the voting obligations set forth in Section 1.1 therein, with respect to all shares of the Company now or hereafter owned or held by Allen & co., such removal and release to be effective as of November 26, 2002. 2. The parties hereto expressly agree and acknowledge that the legend referred to in Section 1.5 of the Agreement shall not be applicable to, and shall not be placed on, certificates representing any shares of the Company now or hereafter owned or held by Allen & Co. 3. Except as specified herein, the parties hereby ratify and affirm each of the other provisions of the Agreement and all other agreements, documents and instruments referred to therein. 4. Nothing contained herein, and neither the failure nor any delay by the Company in exercising any right, power or privilege under this Amendment or the Agreement, shall be construed or shall operate as a waiver of any right, power or privilege, and no single or partial exercise of any such right, power or privilege will preclude any other or further exercise of such right, power or privilege or the exercise of any other right, power or privilege. 5. This Amendment may be executed in two or more counterparts, including by facsimile, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. IN WITNESS WHEREOF, the parties hereto have executed this Amendment effective as of the date first above written. REGEN BIOLOGICS, INC., By: ______________________ Name: Title: ALLEN & COMPANY, INCORPORATION By: _______________________ Name: Title: CENTERPULSE USA HOLDING CO. By: ______________________ Name: Title: J. RICHARD STEADMAN (Additional signatures appear on next page.) SANDERLING VENTURE PARTNERS IV CO-INVESTMENT FUND, L.P. By:_________________ Fred A. Middleton General Partner SANDERLING IV BIOMEDICAL CO-INVESTMENT FUND, L.P. By:__________________ Fred A. Middleton General Partner SANDERLING IV VENTURE MANAGEMENT By:_____________________ Fred A. Middleton Owner SANDERLING VENTURE PARTNERS V CO-INVESTMENT FUND, L.P. By: Middleton, McNeil & Mills Associates, V, LLC By:____________________ Robert G. McNeil Managing Director SANDERLING V BIOMEDICAL CO-INVESTMENT FUND, L.P. By: Middleton, McNeil & Mills Associates V, LLC By:____________________ Robert G. McNeil Managing Director SANDERLING V LIMITED PARTNERSHIP By: Middleton, McNeil & Mills Associates V, LLC By:________________________ Robert G. McNeil Managing Director SANDERLING V BETEILIGUNGS GMBH & CO. KG By: Middleton, McNeil & Mills Associates V, LLC By:_______________________ Robert G. McNeil Managing Director SANDERLING V VENTURES MANAGEMENT By:______________________ Robert G. McNeil Owner SANDERLING VENTURES PARTNERS II, L.P. By:______________________ Robert G. McNeil General Partner SANDERLING VENTURES LIMITED, L.P. By:______________________ Robert G. McNeil General Partner EX-10 5 ex2reg03.txt EX10.1 AMENDED STOCK PURCHASE AGREEMENT Exhibit 5 REGEN BIOLOGICS, INC. SERIES C CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT Dated as of September __, 2003 REGEN BIOLOGICS, INC. SERIES C CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT This Agreement, dated as of September 9, 2003, is entered into by and among ReGen Biologics, Inc., a Delaware corporation (the "Company"), and the individuals and entities listed on Exhibit A hereto (each a "Purchaser" and collectively, the "Purchasers"). In consideration of the mutual promises and covenants contained in this Agreement, the parties agree as follows: 1. Authorization and Sale of Shares and Warrants. 1.1 Authorization. The Company has, or before the Closing (as defined in Section 2) will have, duly authorized the sale and issuance, pursuant to the terms of this Agreement, of up to 17,900,000 million shares of its Series C Convertible Preferred Stock, $0.01 par value per share (the "Series C Preferred"), having the rights, restrictions, privileges and preferences set forth in the Certificate of Designations, Preferences and Rights of Series C Convertible Preferred Stock of the Company attached hereto as Exhibit B (the "Certificate of Designations"). The Company has, or before the Closing will have, adopted and filed the Certificate of Designations with the Secretary of State of the State of Delaware. 1.2 Sale of Shares and Warrants. Subject to the terms and conditions of this Agreement, at the Closing the Company will sell and issue to each of the Purchasers, and each of the Purchasers will purchase from the Company, (i) the number of shares of Series C Preferred set forth opposite such Purchaser's name on Exhibit A for the purchase price of $0.4481 per share (the "Purchase Price") such number of shares to be determined by rounding down any fractional shares to the nearest whole number; and (ii) a warrant, substantially in the form attached hereto as Exhibit C (a "Warrant"), to purchase its pro rata portion of an aggregate of 1,600,000 shares of common stock, par value $0.01 per share of the Company (the "Common Stock"), such pro rata portion will be determined according to such Purchaser's percentage of participation in the Closing as defined in Section 2 hereof. The shares of Series C Preferred sold under this Agreement are referred to as the "Shares." The Company's agreement with each of the Purchasers is a separate agreement, and the sale of Shares to each of the Purchasers is a separate sale. 2. The Closing. The closing (the "Closing") of the sale and purchase of the Shares under this Agreement shall take place at the offices of Shaw Pittman LLP, 1650 Tysons Blvd., McLean, Virginia, at such time, date and place and in such manner, including via facsimile or electronic delivery, as are mutually agreeable to the Company and the Purchasers, but in no event later than September 30, 2003. At the Closing, the Company shall deliver to each of the Purchasers a certificate for the number of Shares and a Warrant being purchased at the Closing by such Purchaser, registered in the name of such Purchaser and a Warrant, against payment to the Company of the Purchase Price, by wire transfer or other method acceptable to the Company. The date of the Closing is hereinafter referred to as the "Closing Date." The Company may sell up to the balance of the authorized number of shares of Series C Preferred not sold at the Closing to additional purchasers at a price not less than $0.4481 per share. 3. Representations, Warranties and Covenants of the Company. Except as and to the extent set forth in the Disclosure Schedule delivered to the Purchasers concurrently herewith, the Company represents and warrants as follows: 3.1 Organization and Good Standing. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has full corporate power and corporate authority to carry on its business as it is now being conducted or is proposed to be conducted, and to own the properties and assets that it now owns. The Company is duly qualified and authorized to do business, and is in good standing as a foreign corporation, in each jurisdiction where the nature of its activities and of its properties makes such qualification necessary and where a failure to so qualify would have a material adverse effect on the Company's business or properties. Copies of the Company's original Certificate of Incorporation, as amended and restated to date (the "Certificate of Incorporation"), and its bylaws, as amended and restated to date (the "Bylaws"), heretofore delivered to the Purchasers, are complete and correct copies of such instruments as presently in effect. The Company has no subsidiaries other than those listed in Section 3.6 and does not otherwise own or control any equity interest in any corporation or other business entity. 3.2 Power and Authority; Enforceability. (a) The Company has full corporate power and authority to enter into this Agreement to issue the Shares and Warrants hereunder and to carry out the transactions contemplated hereby. The Company and its stockholders have, or by the Closing will have, taken all action required by law, its Certificate of Incorporation or its Bylaws to authorize the execution and delivery of this Agreement, the issuance of the Shares and Warrants pursuant to the terms hereof, and the consummation of the transactions contemplated hereby. This Agreement and the Registration Rights Agreement, as defined in Section 5.4, have been duly executed and delivered by the Company and, assuming the valid authorization, execution and delivery of this Agreement by the Purchasers, are valid and binding agreements of the Company, enforceable in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors, as well as judicial principles respecting election of remedies or limiting the availability of specific performance, injunctive relief and other equitable remedies. (b) The Shares, when issued in compliance with the provisions of this Agreement, and the shares of Common Stock issuable upon conversion of the Series C Preferred and exercise of the Warrants (the "Underlying Shares"), when issued upon such conversion in accordance with the terms of the Certificate of Incorporation (i) will be validly issued, fully paid and nonassessable, and (ii) will be free of any liens or encumbrances, other than any liens or encumbrances created by or imposed upon the holders thereof through no action of the Company; provided, however, that the Shares and the Underlying Shares will be subject to restrictions on transfer under state and/or federal securities laws. There are no rights of first refusal held by any stockholders of the Company with respect to the issuance of the Shares. The Shares are not subject to any preemptive rights. 3.3 No Conflicts or Violation. Neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby, will violate any provision of the Certificate of Incorporation or the Bylaws, or violate or be in conflict with, or constitute a default (or an event which, with notice or lapse of time or both, would constitute a default) under, or result in the termination of or accelerate the performance required by, or cause the acceleration of the maturity of any debt or obligation pursuant to, or result in the creation or imposition of any security interest, lien or other encumbrance upon any property or assets of the Company under, any agreement or commitment to which the Company is a party or by which the Company is bound, or to which the property of the Company is subject, which would materially adversely affect the financial condition of the Company, or, to the best knowledge of the Company, violate any statute or law or any judgment, decree, order, regulation or rule of any court or governmental authority. 3.4 Governmental Consents. No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority on the part of the Company is required in connection with the consummation of the transactions contemplated by this Agreement, except for the compliance with notice filing and other requirements under federal and applicable state securities laws, which compliance will have occurred within the appropriate time periods therefor. 3.5 Capitalization. At the Closing, the authorized capital stock of the Company will consist of 117,900,000 shares of Common Stock, and 60,000,000 shares of preferred stock (the "Preferred Stock"), of which 15,298,351 shares will have been designated Series A Convertible Preferred Stock (the "Series A Stock"), of which 15,298,351 shares are outstanding, 30,000,000 shares of which will have been designated as the Series C Preferred. All currently issued and outstanding shares have been issued in compliance with applicable state and federal securities laws. As of the Closing, the Company has reserved for issuance, pursuant to its currently active Stock Option Plans, 8,450,000 shares of Common Stock and has reserved for issuance pursuant to its currently inactive Stock Option Plans 8,443,528 shares of Common Stock. As of the Closing, there are outstanding options and warrants to purchase 12,791,540 and 5,473,554 shares of Common Stock, respectively. Except as contemplated herein, or as set forth on Section 3.5 of the Disclosure Schedule, (i) there are no commitments as of the date hereof pursuant to which the Company is or may become obligated to issue any of its capital stock, (ii) there are no preemptive or similar rights to purchase or otherwise acquire from the Company any shares of capital stock pursuant to any provision of law, the Certificate of Incorporation or Bylaws of the Company, or any agreement to which the Company is a party or otherwise, and (iii) there is no agreement, restriction or encumbrance with respect to the sale or voting of any outstanding shares of the Company's capital stock. Neither the execution and delivery of this Agreement, nor the consummation of the transactions contemplated hereby will result in any antidilution adjustment for the holders of the Company's capital stock or for the holder of any options or warrants to acquire shares of the Company's capital stock. 3.6 Subsidiaries. The Company is the sole holder of the issued and outstanding shares of capital stock of RBio, Inc. and MetaContent, Inc. (each a "Subsidiary" and collectively, the "Subsidiaries"), and the Company holds of record and beneficially owns all of the capital stock of each Subsidiary free and clear of any hypothecation, assignment, deposit arrangement, Lien, preference, priority or other security agreement, warrant, attachment, right of first refusal, preemptive right, conversion, put, call or other restriction on transfer (other than restrictions imposed by federal and state securities laws), or preferential arrangement of any kind or nature whatsoever. There are no proxies, voting rights, stockholders agreements or other agreements or understandings with respect to the voting or transfer of the capital stock of the Subsidiaries. There are no commitments pursuant to which any Subsidiary is or may become obligated to issue any of its capital stock. 3.7 No Undisclosed Liabilities. Neither the Company nor any of its Subsidiaries has any material liabilities or obligations of any nature (whether absolute, accrued, contingent or otherwise) of the type that would be required to be set forth on financial statements in accordance with GAAP, which are not fully reflected on the financial statements which are a part of the Company's annual report on Form 10K/A for the year ended December 31, 2002, filed with the commission on April 14, 2003 or the financial statements which are a part of the quarterly report on Form 10-Q for the quarter ended June 30, 2003, filed with the Commission on August 14, 2003 (collectively, the "Financial Statements") and there are no undisclosed loss contingencies (as such term is used in Statement of Financial Accounting Standards No. 5 ("Statement No. 5") issued by the Financial Accounting Standards Board in March, 1975) which are not adequately provided for in the Financial Statements as required by Statement No. 5. 3.8 Absence of Changes. Except as set forth in Section 3.8 of the Disclosure Schedule, since June 30, 2003, there has not been (a) any material adverse change in the financial condition, results of operations, assets, liabilities or business of the Company or any Subsidiary, (b) any material increase in the liabilities or obligations of the Company or any Subsidiary of any nature whatsoever (contingent or otherwise), (c) any asset or property of the Company or any Subsidiary made subject to a lien of any kind, (d) any waiver of any valuable rights of the Company, or the cancellation of any debts or claims held by the Company or any Subsidiary, (e) any payment of dividends on, or other distributions with respect to, or any direct or indirect redemption or acquisition of, any shares of the capital stock of the Company or any Subsidiary, or any agreement or commitment therefor, (f) any issuance of any stock, bonds or other securities of the Company or any Subsidiary other than pursuant to or in connection with transactions described herein or contemplated by this Agreement, (g) any mortgage, pledge, sale, assignment or transfer of any tangible or intangible assets of the Company or any Subsidiary, (h) any loan by the Company or any Subsidiary to any officer, director, employee or stockholder of the Company or any Subsidiary, or any agreement or commitment therefor, (i) any damage, destruction or loss (whether or not covered by insurance) adversely affecting the assets, property or business of the Company or any Subsidiary, (j) any extraordinary increase in the aggregate amount of salaries or other compensation paid or payable to employees or agents of the Company or any Subsidiary, (k) any change in the accounting methods or practices followed by the Company or any Subsidiary or any theretofore adopted, (l) any capital expenditure in excess of US $75,000, or (m) any commitments with respect to any of the foregoing. 3.9 Encumbrances. Except as set forth in Section 3.9 of the Disclosure Schedule, the Company or its Subsidiaries own outright all the property and assets, real, personal or mixed, tangible or intangible, reflected in the Financial Statements, or not so reflected because not required to be reflected but which are used or useful in the business of the Company or its Subsidiaries, or acquired by the Company or any Subsidiary since June 30, 2003 (in each case other than assets disposed of in the ordinary course of business since June 30, 2003), subject to no mortgages, liens, security interests, pledges, charges or other encumbrances of any kind. 3.10 Litigation. There is no action, suit, customer claim, proceeding or investigation at law or in equity, or by or before any governmental instrumentality or other agency, now pending or threatened against or affecting the Company or any Subsidiary nor, to the best knowledge of the Company, does there exist any basis for any such pending or threatened action, suit, customer claim, proceeding or investigation. Neither the Company nor any of its Subsidiaries is a party to or subject to the provisions of any order, writ, injunction, judgment or decree of any court or governmental agency or instrumentality. 3.11 No Defaults. As of the date hereof, neither the Company nor any of its Subsidiaries is in default (a) under its Certificate of Incorporation as currently in effect or Bylaws, (b) under any indenture, mortgage, lease, purchase or sales order or any other contract, agreement or instrument to which the Company or any Subsidiary is a party or by which it is bound, or any order, writ, injunction, judgment or decree of any court or governmental agency or instrumentality. There exists no condition, event or act which constitutes, or which after notice or lapse of time or both would constitute, a default under any of the foregoing. 3.12 Compliance with Laws. To the best of its knowledge, the Company and each of its Subsidiaries is in compliance with laws, rules, ordinances, governmental regulations and orders of all governmental authorities and/or jurisdictions currently applicable to the conduct of its business as conducted or proposed to be conducted and has all permits, licenses, certificates and authorizations required for the conduct of such business. 3.13 Title to Properties and Assets; Liens, Etc. The Company and each of its Subsidiaries has good and marketable title to its material properties and assets, and has good title to all its leasehold interests, in each case subject to no mortgage, pledge, lien, lease, encumbrance or charge, other than for taxes not yet due or payable or as set forth in the Financial Statements or the notes thereto or in Section 3.13 of the Disclosure Schedule. 3.14 Copyrights, Patents and Other Intangible Assets. (a) Except as set forth in Section 3.14 of the Disclosure Schedule, neither the Company nor its Subsidiaries is obligated to make any payments by way of royalties, fees or otherwise to any owner of, licensor of, or other claimant to, any patent, trademark, proprietary process, trade name, copyright or other intangible asset, with respect to the use thereof or in connection with its business as currently conducted or as proposed to be conducted or otherwise and it has not granted any licenses or manufacturing publication or production rights with respect to its business as currently conducted or as proposed to be conducted. (b) Except as set forth in Section 3.14 of the Disclosure Schedule, the Company and each of its Subsidiaries owns or has the right to use, free and clear of all liens, claims and restrictions, all patents, trademarks, proprietary processes, service marks, trade names, copyrights (and licenses with respect to the foregoing) necessary to its business as now conducted and as proposed to be conducted. Such rights are described in Section 3.14 of the Disclosure Schedule and may be used in the conduct of its business as now conducted or as proposed to be conducted without, to the best of the Company's or applicable Subsidiary's knowledge, infringing upon or otherwise acting adversely to the right or claimed right of any person under or with respect to any of the foregoing. (c) Each employee of the Company and its Subsidiaries has signed a proprietary information agreement, each of which agreements will be in full force and effect as of the Closing. Neither the Company nor any of its Subsidiaries, after reasonable investigation, is aware that any of its employees is or will be in violation thereof, and the Company and each of its Subsidiaries will use its best efforts to prevent any such violation. (d) Neither the Company nor any of its Subsidiaries has received any communications alleging that the Company or any Subsidiary has violated or, by conducting its business as proposed, would violate any of the patents, trademarks, service marks, trade names, copyrights or trade secrets or other proprietary rights of any other person or entity, nor is the Company or any Subsidiary aware of any third party violation of any of the Company's patents, trademarks, service marks, trade names, copyrights or trade secrets or other proprietary rights. Except as set forth in Section 3.14 of the Disclosure Schedule, neither the Company nor any of its Subsidiaries is aware that any of its employees (or any person whom the Company or any Subsidiary presently intends to hire) is obligated under any contract (including licenses, covenants or commitments of any nature) or agreement, or subject to any judgment, decree or order of any court or administrative agency, that would conflict with his obligation to use such employee's best efforts to promote the interests of the Company or any Subsidiary. (e) Except as set forth in Section 3.14 of the Disclosure Schedule, neither the carrying on of the Company's business or any Subsidiary's business by the employees of the Company or any Subsidiary (or persons whom the Company presently intends to hire), nor the conduct of the Company's or any Subsidiary's business as currently conducted or as proposed to be conducted, will, to the Company's or any Subsidiary's knowledge, conflict with or result in a breach of the terms, conditions or provisions of, or constitute a default under, any contract, covenant or instrument under which any of such persons is now obligated. Except as set forth in Section 3.14 of the Disclosure Schedule, neither the Company nor any of its Subsidiaries believe it is or will be necessary to utilize any inventions of any of its employees (or persons it currently intends to hire) made or owned prior to their employment by the Company or any Subsidiary or that it is or will be necessary to utilize any other assets or rights of any of its employees (or persons it currently intends to hire) made or owned prior to their employment with the Company or any Subsidiary in violation of any limitations or restrictions to which any such person is a party or to which any of such assets or rights may be subject. 3.15 Material Agreements. Except as set forth in Section 3.15 of the Disclosure Schedule, neither the Company nor any of its Subsidiaries is a party to any written or oral contract not made in the ordinary course of business and, whether or not made in the ordinary course of business, neither the Company nor any of its Subsidiaries is a party to any written or oral (a) contract with any labor union; (b) contract for the future purchase of fixed assets or for the future purchase of materials, supplies or equipment in excess of US $75,000 per year; (c) contract for the employment of any officer, individual employee or other person on a full-time basis (other than an at-will employment contract) or any contract with any person on a consulting basis; (d) bonus, pension, profit-sharing, retirement, stock purchase, stock option, hospitalization, medical insurance or similar plan, contract or understanding in effect with respect to employees or any of them or the employees of others; (e) agreement or indenture relating to the borrowing of money or to the mortgaging, pledging or otherwise placing a lien on any assets of the Company or any of its Subsidiaries; (f) guaranty by the Company or any of its Subsidiaries of any obligation for borrowed money or otherwise; (g) lease or agreement under which the Company or any of its Subsidiaries is lessee of or holds or operates any property, real or personal, owned by any other party; (h) lease or agreement under which the Company or any of its Subsidiaries is lessor of or permits any third party to hold or operate any property, real or personal, owned or controlled by the Company or any of its Subsidiaries; (i) agreement or other commitment for capital expenditures; (j) contract, agreement or commitment under which the Company or any of its Subsidiaries is obligated to pay any brokers fees, finder's fees or any such similar fees to any third party; (k) contract, agreement or commitment under which the Company or any of its Subsidiaries has issued, or may become obligated to issue any shares of capital stock of the Company or any of its Subsidiaries , or any warrants, options, convertible securities or other commitments pursuant to which the Company or any of its Subsidiaries is or may become obligated to issue any of its securities except as are referred to in this Agreement; or (1) any other contract, agreement, arrangement or understanding which is material to the business of the Company or any of its Subsidiaries or which is material to, and which a prudent investor would need to review in order to make, an informed investment decision with respect to the purchase of the Shares hereunder. 3.16 Registration Rights; Co-Sale Rights. Except as set forth in the Section 3.16 of the Disclosure Schedule, neither the Company nor any of its Subsidiaries is under any contractual obligation to register for sale under the Securities Act of 1933, as amended (the "Act"), any of its presently outstanding securities or any of its securities which may hereafter be issued. Assuming the accuracy of the Purchasers' representations to the Company, no registration of the Series C Preferred Stock issued and sold pursuant to this Agreement will be required. Except as set forth in Section 3.16 of the Disclosure Schedule, and except as limited by state and Federal law, there are no obligations, contractual arrangements or other understandings with respect to the alienability or voting of the Company's or any of its Subsidiaries' Common Stock or Preferred Stock. 3.17 Brokers or Finders; Other Offers. Except for fees payable to Harris Nesbitt Gerard, Inc. and Vail Securities Investment, Inc., neither the Company nor any of its Subsidiaries has incurred, or will incur, directly or indirectly, as a result of any action taken by the Company or any of its Subsidiaries, any liability for brokerage or finders' fees or agents' commissions or any similar charges in connection with this Agreement. 3.18 Tax Returns and Payments. The Company and each of its Subsidiaries have accurately prepared and timely filed all tax returns (federal, state and local) required to be filed by it. All taxes shown to be due and payable on said returns, any assessments, fees or charges and all other taxes due and payable by the Company or any Subsidiary on or before the date hereof have been paid prior to the Company or any of its Subsidiaries becoming delinquent. No deficiency assessment or proposed adjustment of the Company's or any of it Subsidiaries' federal, state or local taxes is pending, and neither the Company nor any of its Subsidiaries has knowledge of any proposed liability for any tax to be imposed upon it, its properties or assets for which it does not have an adequate reserve reflected in the Financial Statements. To the best of the Company's or any of its Subsidiaries knowledge, none of the federal or state income tax returns or state franchise tax returns of the Company or any Subsidiary has ever been audited by federal or state tax officials, respectively. 3.19 Insurance. The Company and each of its Subsidiaries maintains insurance coverage reasonably adequate for the operation of its business (taking into account the cost and availability of such insurance). 3.20 Environmental and Safety Laws. To the best of its knowledge, neither the Company nor any of its Subsidiaries is in violation of any applicable statute, law or regulation relating to the environment or occupational health and safety, and to the best of its knowledge, no material expenditures are or will be required in order to comply with any such existing statute, law or regulation. 3.21 Commission Documents. (a) The Company has filed all required reports, schedules, forms, statements and other documents (including exhibits and all other information incorporated therein) with the Commission since December 31, 2002 (the "Company SEC Documents"). As of their respective dates, the Company SEC Documents complied in all material respects with the requirements of the Act or the Securities Exchange Act of 1934, as amended and the Regulations (as defined in Section 4.4), as the case may be, and none of the Company SEC Documents when filed (unless amended or superseded by a Company Filed SEC Document filed prior to the date hereof, then on the date of such later filing) contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. Except to the extent that information contained in a Company SEC Document has been revised or superseded in a subsequently filed Company SEC Document, none of the Company SEC Documents contains any untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. (b) The Financial Statements of the Company included in the Company SEC Documents complied as to form, as of their respective dates of filing with the Commission, in all material respects with applicable accounting requirements and the published rules and regulations of the Commission with respect thereto (the "Accounting Rules"), have been prepared in accordance with GAAP (except, in the case of unaudited statements, as permitted by Form 10-Q of the Commission) applied on a consistent basis during the periods involved (except as may be indicated in the notes thereto) and fairly present, in all material respects, the consolidated financial position of the Company and its consolidated Subsidiaries as of the dates thereof and the consolidated results of their operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal recurring non-material year-end audit adjustments). 3.22 Full Disclosure. This Agreement, the representations and warranties by the Company contained herein, the Disclosure Schedule and the Exhibits hereto, and all certificates expressly required to be delivered or to be furnished to the Purchasers pursuant to this Agreement, when read together, do not contain any untrue statement of material fact or omit to state a material fact necessary in order to make the statements contained herein or therein not misleading. 4. Representations, Warranties and Covenants of the Purchasers. Each Purchaser severally represents, warrants and agrees as follows: 4.1 Information. Each Purchaser represents that it has had an opportunity to ask questions of the principal officers of the Company and to obtain any additional information necessary to permit an informed evaluation of the benefits and risks associated with the investment made hereby. Each Purchaser has made its own independent investigation of the Company and is aware of the Company's proposed business and financial condition. The foregoing, however, does not limit or modify the representations and warranties of the Company in Section 3 herein or the right of the Purchasers to rely thereon. 4.2 Accredited Investors. Each Purchaser represents that it is an accredited investor within the meaning of the Act and Regulation D thereunder, or by reason of its business or financial experience, or the business or financial experience of its professional advisor, it has the capacity to protect its own interests in connection with this transaction. 4.3 Experience. Each Purchaser represents that it has had sufficient experience in business, financial and investment matters to evaluate the merits and risks involved in the investment made hereby and further represents that it is able to bear the economic risk of such investment for an indefinite period of time or to lose the entire investment made hereby, and has the capacity to protect its own interests in connection with the transactions contemplated herein. 4.4 Investment Intent. Each Purchaser represents that it is acquiring the Shares for its own account and not with a view to any sale or distribution thereof within the meaning of the Act, and the rules and regulations of the Securities and Exchange Commission (the "Commission") thereunder as amended from time to time (the "Regulations"), except to the extent permitted by the Act and the Regulations. Each Purchaser agrees that it will make no sale, offer to sell or transfer of any Shares in violation of the Act, the Regulations or any other federal or state securities law, and each Purchaser understands that certificates representing the same will bear a legend to such effect. 4.5 Restriction on Transfer. Each Purchaser understands that none of the Shares nor the offer and sale thereof, has been registered under the Act or the securities laws of any state and there is at the date hereof no public market for such securities. Each Purchaser further understands and agrees that none of the Shares may be sold, offered for sale or transferred in any manner for an indefinite period of time unless and until (a) a registration statement with respect thereto is in effect under the Act and applicable state laws, or (b) it has been established to the reasonable satisfaction of the Company and its counsel that the proposed transaction is exempt from registration under the Act and applicable state laws or that registration under the Act and applicable state laws is not required. 4.6 Binding Effect, etc. Each Purchaser represents that (a) such Purchaser has full power and authority to purchase such Shares, (b) such Purchaser's agreement to purchase the Shares constitutes a valid and binding agreement enforceable in accordance with its terms, and (c) the purchase of the Shares as contemplated hereby will not conflict with or otherwise violate any charter documents or any other obligations of such Purchaser. 5. Conditions to the Obligations of the Purchasers. The obligation of each of the Purchasers under Section 1.2 of this Agreement is subject to the fulfillment, or the waiver by such Purchaser, of each of the following conditions on or before the Closing: 5.1 Accuracy of Representations and Warranties. Each representation and warranty contained in Section 3 shall be true on and as of the Closing Date with the same effect as though such representation and warranty had been made on and as of that date. 5.2 Performance. The Company shall have performed and complied with all agreements and conditions contained in this Agreement required to be performed or complied with by the Company prior to or at the Closing. 5.3 Certificates and Documents. The Company shall have delivered to the Purchasers: (a) The Certificate of Incorporation of the Company, as amended and restated and in effect as of the Closing Date (including Certificates of Designations), certified by the Secretary of State of the State of Delaware; (b) The Bylaws of the Company, as amended and restated and in effect as of the Closing Date, certified by its Secretary as of the Closing Date; and (c) Resolutions of the Board of Directors of the Company, authorizing and approving all matters in connection with this Agreement and the transactions contemplated hereby, certified by the Secretary of the Company as of the Closing Date. 5.4 Registration Rights Agreement. The Company shall have entered into an Amended and Restated Registration Rights Agreement (each a "Registration Rights Agreement" and collectively, the "Registration Rights Agreements") with each Purchaser substantially in the form attached hereto as Exhibit D. 5.5 Opinion of Counsel. Purchasers shall have received from Shaw Pittman, LLP, special counsel to the Company, an opinion dated as of the Closing, in a form set forth as Exhibit E. 5.6 Compliance Certificates. The Company shall have delivered to the Purchasers a certificate, executed by the President of the Company, dated the Closing Date, certifying to the fulfillment of the conditions specified in paragraphs 5.1, 5.2 and 5.3 of this Agreement. 5.7 Other Matters. All corporate and other proceedings in connection with the transactions contemplated by this Agreement and all documents and instruments incident to such transactions shall be reasonably satisfactory in substance and form to the Purchasers and their counsel, and the Purchasers and their counsel shall have received all such counterpart originals or certified or other copies of such documents as they may reasonably request. 6. Condition to the Obligations of the Company. The obligations of the Company under Section 1.2 of this Agreement are subject to the fulfillment, or the waiver by the Company, of the following condition on or before the Closing: 6.1 Accuracy of Representations and Warranties. The representations and warranties of the Purchasers contained in Section 4 shall be true on and as of the Closing Date with the same effect as though such representations and warranties had been made on and as of that date. 7. Transfer of Shares. 7.1 Restricted Shares. "Restricted Shares" means (i) the Shares, (ii) the shares of Common Stock issued or issuable upon conversion or exercise of the Shares or the Warrants, (iii) any shares of capital stock of the Company acquired by the Purchasers pursuant to any other agreement or instrument, and (iv) any other shares of capital stock of the Company issued in respect of such shares (as a result of stock splits, stock dividends, reclassifications, recapitalizations, or similar events). 7.2 Requirements for Transfer. (a) Restricted Shares shall not be sold or transferred unless either (i) they first shall have been registered under the Act, or (ii) the Company first shall have been furnished with an opinion of legal counsel, reasonably satisfactory to the Company, to the effect that such sale or transfer is exempt from the registration requirements of the Act. (b) Notwithstanding the foregoing, no registration or opinion of counsel shall be required for (i) a transfer by a Purchaser which is a corporation to a wholly owned subsidiary of such corporation, a transfer by a Purchaser which is a partnership to a partner of such partnership or a retired partner of such partnership who retires after the date hereof, or to the estate of any such partner or retired partner, or a transfer by a Purchaser which is a limited liability company to (a) a member or officer of such limited liability company, (b) a retired member who resigns after the date hereof or to the estate of any such member or (c) a retired member; provided that the transferee in each case agrees in writing to be subject to the terms of this Section 7 to the same extent as if it were the original Purchaser hereunder, or (ii) a transfer made in accordance with Rule 144 under the Act. 7.3 Legend. Each certificate representing Restricted Shares shall bear a legend substantially in the following form: "THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL SUCH SHARES ARE REGISTERED UNDER SUCH ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY IS OBTAINED TO THE EFFECT THAT SUCH REGISTRATION IS NOT REQUIRED." The foregoing legend shall be removed from the certificates representing any Restricted Shares, at the request of the holder thereof, at such time as they become eligible for resale pursuant to Rule 144(k) under the Act. 8. Miscellaneous. 8.1 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and permitted assigns. This Agreement, and the rights and obligations of each Purchaser hereunder, may be assigned by such Purchaser to any person or entity to which Shares are transferred by such Purchaser, and such transferee shall be deemed a "Purchaser" for purposes of this Agreement; provided that the transferee provides written notice of such assignment to the Company. The Company may not assign its rights under this Agreement. 8.2 Confidentiality. Each Purchaser agrees that he, she or it will keep confidential and will not disclose, divulge or use for any purpose other than to monitor his, her or its investment in the Company any confidential, proprietary or secret information which such Purchaser may obtain from the Company pursuant to financial statements, reports and other materials submitted by the Company to such Purchaser pursuant to this Agreement or otherwise ("Confidential Information"), unless such Confidential Information is known, or until such Confidential Information becomes known, to the public (other than as a result of a breach of this Section 8.2 by such Purchaser); provided, however, that a Purchaser may disclose Confidential Information (i) to such Purchaser's attorneys, accountants, consultants and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company, (ii) to any prospective purchaser of any Shares from such Purchaser, provided that such prospective purchaser agrees in writing to be bound by the provisions of this Section 8.2, (iii) to any affiliate of such Purchaser or to a partner, stockholder or subsidiary of such Purchaser, provided that such affiliate agrees in writing to be bound by the provisions of this Section 8.2, or (iv) as may otherwise be required by law, provided that the Purchaser takes reasonable steps to minimize the extent of any such required disclosure. Notwithstanding any other provisions of this Section 8.2, a Purchaser shall be free to use the Residuals (as defined below) of any Confidential Information for any purpose, subject only to any patents or copyrights of the Company in such Confidential Information. The term "Residuals" shall mean any information in non-tangible form which is retained in the memory of a Purchaser or any partner, officer, employee or representative of a Purchaser. 8.3 Survival of Representations and Warranties. All agreements, representations and warranties contained herein shall survive the execution and delivery of this Agreement and the Closing of the transactions contemplated hereby until thirty (30) days following the date on which the Form 10-K for ReGen Biologics for the fiscal year ended December 31, 2003 shall have been filed with the Commission; provided, however, that the representation and warranties of Section 3.2 of this Agreement shall survive indefinitely. 8.4 Expenses. The Company shall pay, at the Closing, the reasonable fees, up to a maximum of US $ 25,000 including fees, expenses and disbursements, related to the representation of the Purchasers, such representatives to be designated by the Purchasers, in connection with the preparation of this Agreement and the other agreements contemplated hereby and thereby and the closing of the transactions contemplated hereby and thereby. 8.5 Brokers. Each Purchaser represents and warrants to the other parties hereto that he, she or it has not retained a finder or broker in connection with the transactions contemplated by this Agreement, and the Company and each of the Purchasers agrees that such party will indemnify and save the other parties harmless from and against any and all claims, liabilities or obligations with respect to brokerage or finders' fees or commissions, or consulting fees in connection with the transactions contemplated by this Agreement asserted by any person on the basis of any statement or representation alleged to have been made by such indemnifying party. 8.6 Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement. 8.7 Specific Performance. In addition to any and all other remedies that may be available at law in the event of any breach of this Agreement, each Purchaser shall be entitled to specific performance of the agreements and obligations of the Company hereunder and to such other injunctive or other equitable relief as may be granted by a court of competent jurisdiction. 8.8 Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware (without reference to the conflicts of law provisions thereof). 8.9 Notices. All notices, requests, consents, and other communications under this Agreement shall be in writing and shall be deemed delivered (i) two business days after being sent by registered or certified mail, return receipt requested, postage prepaid or (ii) one business day after being sent via a reputable nationwide overnight courier service guaranteeing next business day delivery, in each case to the intended recipient as set forth below: If to the Company, at: 509 Commerce Street, East Wing Franklin Lakes, NJ 07417 Facsimile: (201) 651-5141 Attention: Gerald E. Bisbee, Jr., Ph.D, or at such other address or addresses as may have been furnished in writing by the Company to the Purchasers; If to a Purchaser, at the address set forth on Exhibit A for such Purchaser, or at such other address or addresses as may have been furnished to the Company in writing by such Purchaser. Any party may give any notice, request, consent or other communication under this Agreement using any other means (including, without limitation, personal delivery, messenger service, telecopy, first class mail or electronic mail), but no such notice, request, consent or other communication shall be deemed to have been duly given unless and until it is actually received by the party for whom it is intended. Any party may change the address to which notices, requests, consents or other communications hereunder are to be delivered by giving the other parties notice in the manner set forth in this Section. 8.10 Complete Agreement. This Agreement (including its Exhibits and the Disclosure Schedule delivered in accordance herewith) constitutes the entire agreement and understanding of the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings relating to such subject matter. 8.11 Amendments and Waivers. Except as otherwise expressly set forth in this Agreement, any term of this Agreement may be amended or terminated and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company and the holders of at least 50% of the shares of Common Stock issued or issuable upon conversion of the Shares. Notwithstanding the foregoing, this Agreement may be amended with the consent of the holders of less than all of the shares of Common Stock issued or issuable upon conversion of the Shares only in a manner which applies to all such holders in the same fashion and any amendment, termination or waiver effected in accordance with this Section 8.11 shall be binding upon each holder of any Shares (including shares of Common Stock into which such Shares have been converted) even if they do not execute such consent, each future holder of all such securities and the Company. No waivers of or exceptions to any term, condition or provision of this Agreement, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such term, condition or provision. 8.12 Pronouns. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns and pronouns shall include the plural, and vice versa. 8.13 Counterparts; Facsimile Signatures. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, and all of which shall constitute one and the same document. This Agreement may be executed by facsimile signatures. 8.14 Section Headings. The section headings are for the convenience of the parties only and in no way alter, modify, amend, limit, or restrict the contractual obligations of the parties. [Signature Page to Follow] IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written. ReGen Biologics, Inc. By: Name: Gerald E. Bisbee, Jr., Ph.D. Title: President, Chief Executive Officer and Chairman PURCHASERS: If Individual: Print Name: Signature: Contact Information: Dollar Amount Purchased: If Corporation, Partnership, Limited Liability Company or Other Entity: Print Name of Entity: Signature By: Contact Information: Dollar Amount Purchased: PURCHASERS: If Individual: Print Name: Signature: Contact Information: Dollar Amount Purchased: If Corporation, Partnership, Limited Liability Company or Other Entity: Print Name of Entity: Signature By: Contact Information: Dollar Amount Purchased: A-2 EXHIBIT A Purchasers
Name Number of Shares of Series C Preferred Dollar Amount Purchased Sanderling Companies 5,021,200 $ 2,250,000.00 J.F. Shea Co. 223,164 100,000.00 Arthur Rock 312,430 140,000.00 F. Warren Hellman 171,836 77,000.00 William R. and Judith P. Timken, 223,164 100,000.00 Trustees of Timkin Living Trust U/A/D 1949 J. Richard Steadman 111,582 50,000.00 Howard Berkowitz 223,164 100,000.00 Richard Harris 223,164 100,000.00 Dr. Charles Ho 223,164 100,000.00 Ingram Family Trust 22,316 10,000.00 Mervyn Lapin PSP 111,582 50,000.00 John M. Angelo 301,272 135,000.00 Judith H. Angelo 100,424 45,000.00 John M. Angelo, Maurice R. Povich 446,328 200,000.00 TTTIC ANNUMC LLLP c/o Scott 55,791 25,000.00 Balcomb Neil Austrian 55,791 25,000.00 Charles N. Blitzer 133,898 60,000.00 Bravo Colorado Music Festival 111,582 50,000.00 Endowment Mary Ellen Canniff 22,316 10,000.00 William Clinkenbeard 100,000 44,810.00 Marcia Diamond Trust 301,272 135,000.00 Lawrence A. Gordon 200,848 90,000.00 David A. Gordon 44,588 19,980.00 Michael L. Gordon 468,734 210,040.00 Amy Beth Gordon 44,588 19,980.00 Shelka Gramshammer 33,474 15,000.00 Gary C. Klein 223,164 100,000.00 Ben Kreuger 55,791 25,000.00 Jeffrey Lapin 11,158 5,000.00 Rodney Lapin 17,853 8,000.00 Ranjle Liu 33,474 15,000.00 Donald McMahan 32,135 14,400.00 Elizabeth A. Meyer 40,169 18,000.00 Luc Meyer 338,540 151,700.00 John S. Petrow 111,582 50,000.00 Maurice R. Povich 301,272 135,000.00 Elizabeth W. Slifer 154,652 69,300.00 Richard Stephenson 111,582 50,000.00 Daniel E. Telleen 11,158 5,000.00 Vail Fishing Partners 446,328 200,000.00 George A. Wiegers 55,791 25,000.00 Jerold L. Zaro 111,582 50,000.00 Kathy Weiss 55,791 25,000.00 Todd C. Standbrook 22,316 10,000.00 L-R Global Partners 2,939,542 1,317,209.00 DB Advisors, LLC 557,911 250,000.00 Robert Fraiman 111,582 50,000.00
EXHIBIT B Certificate of Designations EXHIBIT C Warrant EXHIBIT D Registration Rights Agreement EXHIBIT E Legal Opinion -----END PRIVACY-ENHANCED MESSAGE-----